As the pandemic continues to impact the globe, the agency has kept busy issuing EUAs for potential treatments, and cited sellers of unapproved treatments.
Taking place December 9, the Digital Advances in Clinical Trials webinar covers notable advances in clinical trial technology, and the future of the field.
Health tech specialists GoodCell are working with the New York Blood Center to identify COVID-19 patients with elevated risk of adverse clinical outcomes.
A recent survey conducted by Oracle reveals trial professionals’ thoughts, feelings and behavior around decentralized research in the face of the pandemic.
The division of the National Institutes of Health has begun enrolling hospitalized patients in a trial investigating various potential COVID-19 treatments.
The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.
The agency has given the go-ahead for use of baricitinib in conjunction with remdesivir for treating patients hospitalized with severe cases of the virus.
RedHill Biopharma has completed enrollment for its Phase II study exploring the use of opaganib in treating COVID-19 patients that have severe pneumonia.
A leader from the CRO discusses how the COVID-19 pandemic has accelerated decentralized adoption, and how such trials lead to benefits for participants.
According to one New Yorker, encountering the AI-assisted TrialJectory technology helped cut through the uncertainty to provide information and solutions.
The federal agency has offered updates, advice and action regarding the COVID-19 pandemic, helping life-sciences professionals stay on top of developments.
During a free editorial webinar on December 9, a panel of clinical trial experts will offer a range of insights into the future of research technology.